Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials
Molecular target inhibitors have been regularly approved by Food and Drug Administration (FDA) for tumor treatment, and most of them intervene in tumor cell proliferation and metabolism. The RAS–RAF–MEK–ERK pathway is a conserved signaling pathway that plays vital roles in cell proliferation, surviv...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Jezik: | English |
| Izdano: |
KeAi Communications Co., Ltd.
2023-01-01
|
| Serija: | Genes and Diseases |
| Teme: | |
| Online dostop: | http://www.sciencedirect.com/science/article/pii/S2352304222001404 |